Market Overview:

The global peptide therapeutics market reached a value of US$ 35.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 61.9 Billion by 2027, exhibiting a CAGR of 9.42% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor. 

Peptides are efficacious and selective signaling molecules that bind to specific cell surface receptors, such as ion channels and G protein-coupled receptors (GPCRs) and trigger intracellular effects. They are employed in the pharmaceutical industry to design novel regenerative therapeutics that can target a wide range of cells and manipulate their responses. These therapeutics are less toxic, relatively safe, and well-tolerated than other treatment options. As a result, they are gaining traction in clinical practices worldwide to manage cancer, injuries, infectious diseases, metabolic disorders, and aesthetic concerns.

Peptide Therapeutics Market Trends:

The growing prevalence of acute and chronic diseases, along with the rising access to medical facilities, represents one of the leading factors positively influencing the demand for peptides to develop innovative therapies. Moreover, peptides therapies are used in cosmeceutical surgeries to slow down the process of skin aging. This, coupled with the increasing consciousness among individuals about physical appearance and the desire to retain young and healthy skin, is driving the adoption of cosmetic surgeries and peptide therapeutics around the world. Apart from this, with the introduction of novel synthetic strategies that reduce injection frequency and improve stability and other physical properties, peptide therapeutics are widely being used in injections for diabetic patients. This, in confluence with the increasing incidence of diabetes and the growing preference for quick and precise treatment methods, is influencing the use of peptide therapeutics over oral medications. Furthermore, the emerging trend of personalized and targeted treatments is catalyzing the demand for multifunctional peptide-based materials. This, along with the rising funding to develop novel peptide therapeutics for treating autoimmune and inflammatory diseases, is projected to create a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global peptide therapeutics market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on type, type of manufacturer, synthesis technology, routes of administration and application.

Breakup by Type:

• Innovative
• Generic
   

Breakup by Type of Manufacturer:

• Outsourced
• In-house
   

Breakup by Synthesis Technology:

• Solid Phase Peptide Synthesis
• Liquid Phase Peptide Synthesis
• Hybrid Technology
   

Breakup by Routes of Administration:

• Parenteral
• Oral
• Others
   

Breakup by Application:

• Gastrointestinal Disorders
• Neurological Disorders
• Metabolic Disorders
• Cancer
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Apitope International NV, Arch Biopartners Inc., AstraZeneca plc, Circle Pharma Inc., Corden Pharma GmbH, F. Hoffmann-La Roche AG, Ipsen Group, Lonza Group AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Industries Ltd. and Zealand Pharma A/S.

Report Coverage:

Key Questions Answered in This Report:

• How has the global peptide therapeutics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global peptide therapeutics market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the type of manufacturer?
• What is the breakup of the market based on the synthesis technology?
• What is the breakup of the market based on the routes of administration?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global peptide therapeutics market and who are the key players?
• What is the degree of competition in the industry?